A phase I trial of PF-03084014, an oral reversible γ- secretase inhibitor, in solid tumor malignancies shows drug tolerability in patients. Evidence of Notch pathway inhibition was demonstrated in peripheral blood. A surprisingly high rate of response was seen in desmoid tumors, a rare but sometimes locally aggressive sarcoma.
ASJC Scopus subject areas
- Cancer Research